Telomerase inhibitor imetelstat has preclinical activity across the spectrum of non-small cell lung cancer oncogenotypes in a telomere length dependent manner

Telomerase was evaluated as a therapeutic oncotarget by studying the efficacy of the telomerase inhibitor imetelstat in non-small cell lung cancer (NSCLC) cell lines to determine the range of response phenotypes and identify potential biomarkers of response. A panel of 63 NSCLC cell lines was studie...

Descripción completa

Detalles Bibliográficos
Autores principales: Frink, Robin E., Peyton, Michael, Schiller, Joan H., Gazdar, Adi F., Shay, Jerry W., Minna, John D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Priority Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5077965/
https://www.ncbi.nlm.nih.gov/pubmed/27192120
http://dx.doi.org/10.18632/oncotarget.9335

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5077965/
https://www.ncbi.nlm.nih.gov/pubmed/27192120
http://dx.doi.org/10.18632/oncotarget.9335

Ejemplares similares